

2 DFS 81.35%vs44.62% DFS 42.41
vs20.96 OS 5 33.69%
84.78%vs51.09% OS

3.

5

2

NSCLC

50

SCI 91 J Clin Oncol Lancet Respir Med
44.544 93 21 3
1 131 2

10

1.

4 4L

4L

5

4L

2.

IIIA EGFR

NSCLC

EVEN

CSCO

OS

IIIA

1.Chen C Liu WR Zhang B Zhang LM Li CG Liu C Zhang H, Huo YS

Ma YC Tian PF Qi Q Li JJ Tang Z Zhang ZF Giaccone G Yue DS Wang CL. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. *CANCER LETTERS*. 2020 486:58-70.

2.Zhang H, Zhang B, Zhu KK, Wu C, Gao LW, Sun XY, Liu C Wang CL. Preoperative albumin-to-globulin ratio predicts survival in patients with non-small-cell lung cancer after surgery. *JOURNAL OF CELLULAR PHYSIOLOGY*. 2019.234.(3): 2471-2479.

3.Yue DS Xu SD Wang Q Li XF Shen Y Zhao H Chen C Mao WM Liu W Liu JF Zhang LJ Ma HT Li Q Yang Y Liu YY Chen HQ Wang CL. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial. *LANCET RESPIRATORY MEDICINE*. 2018.6.(11):863-873.

4.Wang YN Yao S Wang CL Li MS Sun LN Yan QN Tang SW Zhang ZF. Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer. *JOURNAL OF CLINICAL ONCOLOGY*. 2018.36.(29):2935-+.

5.Huang WH Wang SG Zhang H Zhang B Wang CL. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer. *CANCER BIOLOGY&MEDICINE*. 2018.15.(1):88-96.

6.Yue DS Gong LQ You J Su YJ Zhang ZF Zhang Z Gu F Wang M Wang CL. Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines. *BMC CANCER*. 2014.14

7.
2014.36.(07):532-535.

8. I
. 2009..(04):221-222

9

RNA XLOC_00090

ZL201610896402.3 2019-06-04 CN106282385 B

10

” 2021